Tejwani V, Fawzy A, Putcha N, et al. - Researchers investigated whether use of angiotensin converting enzyme inhibitor (ACEi) and angiotensin-receptor blocker (ARB) was related to less progression of emphysema and FEV ₁ reduction in patients with COPD or baseline emphysema. Participants were selected from the Genetic Epidemiology of COPD Study, and included former and current smokers who attended baseline and 5-year follow-up visits, did not change smoking status, and had chest CT imaging done. Findings revealed slower progression of emphysema and lung function decline in relation to use of ACEi and ARB among participants with spirometry-confirmed COPD or baseline emphysema.